Spoken Alpha
AtriCure, Inc.
AtriCure designs and manufactures surgical devices for treating atrial fibrillation, managing left atrial appendage, and controlling post-operative pain. The company sells ablation systems, appendage exclusion devices, and cryoablation probes to hospitals and surgical centers through direct sales and distributors in the U.S., Europe, Australia, and Canada.
AtriCure, Inc is a Healthcare company operating in Medical Instruments & Supplies with a $2.77B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ATRC.
$ curl https://api.spokenalpha.com/v1/companies/ATRCFAQ
Spoken Alpha indexes ATRC's earnings call transcripts at https://spokenalpha.com/companies/ATRC. Each call links to attributed speakers and parsed analyst Q&A. AtriCure, Inc.'s own investor relations page is at https://ir.atricure.com/.
AtriCure, Inc. (ATRC) held its most recent earnings call on 2026-07-23, covering fiscal Q2 2026.
AtriCure, Inc. (ATRC) operates in the Healthcare sector (Medical Instruments & Supplies industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $0.01 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-22 | $0.18 | $0.03 | +100.0% | $153.6M | — | — | EODHD |
| Q1 FY2026 | 2026-05-04 | $0.00 | $-0.06 | +100.0% | $141.2M | — | — | EODHD |
| Q4 FY2025 | 2026-02-16 | $0.06 | $-0.04 | +100.0% | $140.5M | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $-0.01 | $-0.12 | +91.7% | $134.3M | — | — | EODHD |
| Q2 FY2025 | 2025-07-28 | $-0.02 | $-0.16 | +87.5% | $136.1M | — | — | EODHD |
| Q1 FY2025 | 2025-04-28 | $-0.14 | $-0.22 | +36.4% | $123.6M | — | — | EODHD |
| Q4 FY2024 | 2025-02-12 | $-0.08 | $-0.15 | +46.2% | $124.3M | — | — | EODHD |
| Q3 FY2024 | 2024-10-28 | $-0.17 | $-0.20 | +15.0% | $115.9M | — | — | EODHD |
| Q2 FY2024 | 2024-07-29 | $-0.17 | $-0.17 | 0.0% | $116.3M | — | — | EODHD |
| Q1 FY2024 | 2024-04-30 | $-0.25 | $-0.23 | -8.7% | $108.9M | — | — | EODHD |
| Q4 FY2023 | 2024-02-14 | $-0.21 | $-0.23 | +8.7% | $106.5M | — | — | EODHD |
| Q3 FY2023 | 2023-10-31 | $-0.20 | $-0.31 | +35.5% | $98.3M | — | — | EODHD |
| Q2 FY2023 | 2023-07-24 | $-0.12 | $-0.31 | +61.3% | $100.9M | — | — | EODHD |
| Q1 FY2023 | 2023-05-01 | $-0.23 | $-0.35 | +34.3% | $93.5M | — | — | EODHD |
| Q4 FY2022 | 2023-02-20 | $-0.09 | $-0.18 | +50.0% | $88.0M | — | — | EODHD |
| Q3 FY2022 | 2022-10-31 | $-0.27 | $-0.25 | -8.0% | $83.2M | — | — | EODHD |
| Q2 FY2022 | 2022-08-01 | $-0.32 | $-0.29 | -10.3% | $84.5M | — | — | EODHD |
| Q1 FY2022 | 2022-05-02 | $-0.33 | $-0.34 | +2.9% | $74.6M | — | — | EODHD |
| Q4 FY2021 | 2022-02-14 | $-0.30 | $-0.31 | +3.2% | $73.2M | — | — | EODHD |
Source: EODHD. ATRC reported actuals as published; sparse fields render as —.